

	<b>HLA-B27 – N = 516</b>	<b>Female N = 236</b>	<b>Male N = 280</b>	<b>p-value</b>
<b>Age</b>	43.4 (12.6)	43.6 (12.6)	43.2 (12.7)	0.729
<b>University studies</b>	219 (42.4%)	95 (40.3%)	124 (44.3%)	0.356
<b>Family history of axSpA</b>	79 (15.3%)	37 (15.7%)	42 (15.0%)	0.831
<b>Age of symptoms onset</b>	30.0 (11.1)	30.9 (11.6)	29.3 (10.6)	0.104
<b>Age of diagnosis</b>	37.7 (12.1)	38.5 (12.2)	37.1 (12.0)	0.193
<b>BMI</b>	26.5 (5.6)	26.7 (6.0)	26.3 (5.1)	0.381
<b>Past or current peripheral arthritis</b>	245 (47.5%)	127 (53.8%)	118 (42.1%)	0.008
<b>Past or current enthesitis</b>	292 (56.6%)	138 (58.5%)	154 (55.0%)	0.428
<b>Past or current dactylitis</b>	52 (10.1%)	28 (11.9%)	24 (8.6%)	0.216
<b>Past or current uveitis</b>	59 (11.4%)	28 (11.9%)	31 (11.1%)	0.778
<b>Past or current psoriasis</b>	100 (19.4%)	45 (19.1%)	55 (19.6%)	0.869
<b>Past or current IBD</b>	66 (12.8%)	26 (11.0%)	40 (14.3)	0.268
<b>NSAIDs ever</b>	366 (70.9%)	174 (73.7%)	192 (68.6%)	0.199
<b>csDMARDs ever</b>	316 (61.2%)	148 (62.7%)	168 (60.0%)	0.529
<b>bDMARDs ever</b>	307 (59.5%)	134 (56.8%)	173 (61.8%)	0.249

Supplementary Table 1.0 Gender-based differences in HLA-B\*27 negative patients

	<b>Total N = 2269</b>	<b>HLA-B27 + N = 1753</b>	<b>HLA-B27 – N = 516</b>	<b>p-value</b>
<b>Lines csDMARDs</b>	0.64 (0.78)	0.61 (0.75)	0.72 (0.87)	0.006
<b>&gt;= 2 csDMARDs</b>	290 (12.8%)	209 (11.9%)	81 (15.7%)	0.024
<b>Lines ts/bDMARDs</b>	0.82 (0.98)	0.81 (0.96)	0.86 (1.06)	0.287
<b>&gt;= 2 ts/bDMARDs</b>	369 (12.3%)	274 (15.6%)	95 (18.4%)	0.133

Supplementary Table 2.0 Treatment utilization based on HLA-B\*27 status